Literature DB >> 6498023

[Clinical studies of meningeal gliomatosis].

N Arita, Y Ushio, T Hayakawa, K Yamada, T Yoshimine, S Ko, H Mogami.   

Abstract

Ten (23%) patients out of 43 with malignant glioma developed meningeal gliomatosis during the follow up period of at least one year. The duration between the first surgery and diagnosis of meningeal gliomatosis ranged from one to 78 weeks (median 45 weeks). In younger age group less than 20 years old, 5 (56%) out of 9 patients had meningeal gliomatosis, and on the contrary the incidence was lower in older age group above 20 years old (5 of 34, 15%). Seven (22%) out of 32 male and 3 (27%) out of 11 female patients developed meningeal gliomatosis. The primary tumor location were frontal lobe in 4 cases (including one bifrontal tumor), temporal in 2, parieto-occipital in 1, thalamus in 1, midbrain in 1, and cerebellar hemisphere in 1, respectively. Histologically, 7 tumors were anaplastic astrocytoma, and 3 were glioblastoma. The characteristic neurological findings observed during the course of meningeal gliomatosis were abnormal mental status (80%), cranial nerve palsies (50%), paraplegia (60%), stiff neck (80%), seizure (50%), and respiratory disturbance (80%), CSF cytology was positive in all 9 patients tested. CT scan demonstrated hydrocephalus (70%), and diffuse contrast enhancement of ventricular wall (60%) and basal cistern (10%). In 2 cases, block and irregular filling defect were seen by myelography. Six patients were treated by irradiation to the whole brain and/or spine, and 5, by intrathecal chemotherapy with methotrexate, cytosine arabinoside and bleomycin. However, all patients died of the tumor one to 46 weeks (median 18 weeks) after the diagnosis of meningeal gliomatosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1984        PMID: 6498023

Source DB:  PubMed          Journal:  No To Shinkei        ISSN: 0006-8969


  5 in total

1.  Extensive spinal necrosis with spinal leptomeningeal dissemination of cerebral astrocytoma. Case report.

Authors:  T Yamaki; M Otaki; T Uede; J Niwa; K Hashi; T Uede; K Kikuchi
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

2.  Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.

Authors:  S Mizumatsu; K Matsumoto; Y Ono; T Tamiya; T Furuta; T Ohmoto
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

3.  Pharmacokinetics of intrathecal 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rats.

Authors:  T Y Huang; N Arita; Y Ushio; T Hayakawa; K Yamada
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Intrathecal ACNU--a new therapeutic approach against malignant leptomeningeal tumors.

Authors:  N Arita; Y Ushio; T Hayakawa; M Nagatani; T Y Huang; S Izumoto; H Mogami
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

5.  Intrathecal chemotherapy with ACNU for meningeal gliomatosis.

Authors:  T K Yoshida; E Beuls; K Shimizu; A Koulousakis; V Sturm
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.